Biogen
BIIB
1,016 hedge funds and large institutions have $24.7B invested in Biogen in 2026 Q1 according to their latest regulatory filings, with 113 funds opening new positions, 397 increasing their positions, 293 reducing their positions, and 104 closing their positions.
35% more repeat investments, than reductions
Existing positions increased: 397 | Existing positions reduced: 293
9% more first-time investments, than exits
New positions opened: 113 | Existing positions closed: 104
1% more funds holding
Funds holding: 1,006 → 1,016 (+10)
10% less call options, than puts
Call options by funds: $324M | Put options by funds: $360M
3.31% less ownership
Funds ownership: 95.26% → 91.95% (-3.3%)
18% less capital inflows, than outflows
Capital inflows: $1.83B | Capital outflows: $2.24B
20% less funds holding in top 10
Funds holding in top 10: 10 → 8 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$623M |
| 2 |
BlackRock
New York
|
+$214M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$72.8M |
| 4 |
Artemis Investment Management
Edinburgh,
United Kingdom
|
+$63.5M |
| 5 |
Sofinnova Investments
Menlo Park,
California
|
+$42.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$369M |
| 2 |
Millennium Management
New York
|
-$190M |
| 3 |
Barclays
London,
United Kingdom
|
-$139M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$109M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$96.1M |
BIIB Hedge Fund Activity: Q1 2026 in Review
1,016 of the 8,241 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q1 2026, worth a combined $24.7B — up 0.6% from $24.6B a quarter earlier.
Buyers outnumbered sellers: 113 funds opened new BIIB positions and 104 closed out — a net gain of 9 holders — while 397 added to existing stakes and 293 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $623M. The largest seller was Point72 Asset Management, cutting an estimated $369M.
- 1,016 institutional investors held Biogen (BIIB) as of Q1 2026, up from 1,006 in Q4 2025.
- Funds reported $24.7B of Biogen stock for Q1 2026, up 0.6% quarter-over-quarter.
- 113 funds opened new Biogen positions in Q1 2026 and 104 closed out, a net change of +9 holders.
- The largest Biogen buyer in Q1 2026 was Fidelity Investments, an estimated $623M added.
- The largest Biogen seller in Q1 2026 was Point72 Asset Management, an estimated $369M sold.
Based on aggregated 13F filings for Q1 2026.